ArticleEuropean radiology2026
Prognostic value of imaging-detected immune-related adverse events in biliary tract cancer patients receiving durvalumab-based chemotherapy.
Article in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Commented on by
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study aimed to evaluate the incidence and prognostic significance of imaging-detected immune-related adverse events (irAEs) in patients with unresectable biliary tract cancer (BTC) receiving durvalumab combined with gemcitabine and cisplatin. MATERIALS AND
methodsThis retrospective cohort study included 66 patients (mean age ± standard deviation, 64.7 ± 9.4 years, 35 women) with histologically confirmed unresectable BTC who received a combination of durvalumab, gemcitabine, and cisplatin as the first-line systemic therapy. Clinical records and imaging studies were reviewed to identify irAEs. The primary endpoint was overall survival (OS); secondary endpoints included progression-free survival (PFS), treatment response, and incidence of irAEs. Cox regression analyses were conducted to determine predictors of survival outcomes.
resultsImaging-detected irAEs were observed in 21.2% (14/66) of patients, with the most frequent findings being bowel wall thickening and transient inflammatory lung nodules. The majority of these events (85.7%) manifested within 90 days of treatment initiation, and only 35.7% (5/14) had clinical symptoms related to irAE. In multivariate analysis, the presence of imaging-detected irAEs was a significant independent predictor of improved OS (hazard ratio (HR) = 0.42; p = 0.017) and PFS (HR = 0.43; p = 0.016). The median OS was significantly longer in patients with imaging-detected irAEs compared to those without (23.0 vs. 12.0 months; p = 0.009).
conclusionImaging-detected irAEs are potent prognostic markers for superior survival in BTC patients receiving durvalumab-based chemotherapy. Given that these events are frequently subclinical and occur early in the treatment course, meticulous radiologic surveillance is essential to identify patients likely to achieve favorable clinical outcomes. KEY POINTS: Question The relationship between immune-related adverse events (irAEs) on imaging and treatment outcome in biliary tract cancer patients undergoing durvalumab-based therapy has not been thoroughly investigated. Findings The development of irAEs detected on imaging study was significantly associated with improved overall survival. Clinical relevance Careful imaging evaluation during follow-up to detect early irAE-related change is important, since the occurrence of irAEs may indicate better clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.